

**INSTITUTIONAL BIOSAFETY COMMITTEE
IBC MEETING MINUTES**

July 9, 2026

MEMBERS PRESENT: JoEllyn McMillan – Chair, Eric Bradley, Sandipan Brahma, Paul Davis, Ryan Duden, Jared Evans, Noel Johnson, Jim Kee, Mimi McCann, Jenna McKenzie, Jim Talmadge, Vinai Thomas

NON-VOTING ALTERNATE MEMBERS PRESENT: Mackenzie Conrin

ADMINISTRATIVE STAFF PRESENT: Jackie Hollinger, Sue Logson, Makayla Walker

GUESTS PRESENT: Stephen Asante-Adde, Jacki Haley, Ashley Green

Dr. McMillan opened the meeting at 2:33pm.

A. Review and Acceptance of IBC Minutes

The IBC voted (12 in favor, 0 against, 0 abstention) to accept June 11, 2026 minutes.

B. Information, Education and Policy Items

Introduction of new Kearney IBC community members: Jacki Haley and Ashley Green

C. Special Notification/Review

none

D. Incident and Event Reports Special Notification and/or Review Approved

none

E. IBC Initial Research Proposals and/or Previously Tabled

1) IBC#: 26-06-014-ABL2

PI: Ahodantin, James

Title: Deciphering Mechanisms of HIV Immunopathology and Therapy

Biohazardous Agents: Human immunodeficiency virus types 1 and 2 (not concentrated)

Applicable NIH Guidelines: Exempt

Summary: The protocol describes studies to investigate the interaction of HIV infection and development of chronic liver disease. Humanized mouse models HIV, and EcoHIV are used.

Committee Recommendation: To streamline communication, the committee recommended that the PI contact the biosafety team to work through the questions and comments from the review.

Training: All training is completed and up to date.

Motion: Tabled

Vote Counts: 12-0-0

2) **IBC#:** 26-06-015-BL2

PI: Oupicky, David

Title: Utilizing lentiviral and AAV vectors for CRISPR-mediated gene editing in primary neurons and T-cells

Biohazardous Agents: Adeno-associated virus, CRISPR System Lentivirus-based, Human cell line/cells/tissues, Lentivirus, not HIV, Murine Primary Cells, Lentiviral Vector

Applicable NIH Guidelines: III-D-1-a, III-D-3-a

Summary: This protocol describes studies to use lentivirus and AAV vectors to deliver CRISPR gene editing systems to 1.) commercially acquired human iPSC-derived neurons to investigate the effects of upregulating endogenous Klotho expression on Alzheimer's Disease phenotypes in the neurons and 2.) primary murine CD8+ T cells to investigate a novel therapeutic target in the context of mutant isocitrate dehydrogenase (IDH) glioma and T cell effector function.

Committee Recommendation: None.

Training: All training is complete and up to date.

Motion: Approved

Vote Counts: 12-0-0

3) **IBC#:** 26-06-016-BL2

PI: Cross, Shaun

Title: Extraction and surveillance of microbes in kissing bugs

Biohazardous Agents: Arthropods, extracted total nucleic acids, Kissing Bugs (*Triatoma* spp.), *Trypanosoma cruzi* (extracted genomic DNA)

Applicable NIH Guidelines: exempt

Summary: This protocol describes studies to extract DNA from kissing bugs to screen for the presence of *Trypanosoma cruzi* and other microbes. Kissing bugs collected, frozen and stored in 70% ethanol by external collaborators will be used.

Committee Recommendation: None

Training: All training is complete and up to date.

Motion: Approved

Vote Counts: 12-0-0

F. IBC Change in Protocol

4) **IBC#:** 23-11-031-BL2

PI: Medlin, Jennifer

Title: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases

Biohazardous Agents: Human cell line/cells/tissues

Applicable NIH Guidelines: III-C-1

Summary: Clinical trial evaluating FT819 as CAR-T intervention for B-cell mediated autoimmune diseases. Adding Kearney NM location.

Committee Recommendation: None.

Training: All training is complete and up to date.

Motion: Approved

Vote Counts: 12-0-0

5) **IBC#:** 25-02-009-ABL2

PI: Kumbar, Sangamesh

Title: Bioactive Materials for Wound Healing

Biohazardous Agents: *Enterobacter* species, *Enterococcus* species, *Escherichia coli*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, methicillin-resistant

Applicable NIH Guidelines: Exempt

Summary: This protocol examines the formation of biofilms in infected skin lesions. Normal and diabetic rats will be infected with different bacterial species (all BSL2) and biofilm formation will be assessed.

Committee Recommendation: Several concerns were raised during the review. To streamline communication, they were asked to communicate with the Biosafety Team to work through IBC comments and questions.

Training: All training is complete and up to date.

Motion: Tabled

Vote Counts: 12-0-0

6) **IBC#:** 26-01-001-BL3

PI: Broadhurst, Jana

Title: Hemagglutination and hemagglutination inhibition assay to quantify neutralizing antibodies to influenza A viruses in human blood

Biohazardous Agents: Chicken tissues/cells, Influenza viruses (highly pathogenic), Influenza viruses (not highly pathogenic), Porcine cells/tissues.

Applicable NIH Guidelines: Exempt

Summary: This protocol describes work to correlate antibody binding data from a bead-based influenza antibody capture assay (IBC assay) with functional antibody activity measured by the hemagglutination inhibition (HAI) assay. Specifically, the work will assess whether antibody capture to hemagglutinin proteins on Luminex beads predicts the ability of antibodies to neutralize influenza A virus (IAV) strains.

Committee Recommendation: None

Training: All training is complete and up to date.

Motion: Approved

Vote Counts: 12-0-0

G. IBC Continuing Review Active Research

7) **IBC#:** 20-03-022-BL2

PI: Broadhurst, Jana

Title: Detection of antibodies targeting pathogens of interest

Biohazardous Agents: Hantavirus: Andes Strain, Hantavirus: Sin Nombre Virus, Human cell line/cells/tissues, Influenza viruses (not highly pathogenic), SARS-CoV-2 (clinical specimen)

Applicable NIH Guidelines: Exempt

Summary: This protocol addresses work with samples that may contain pathogens that can be safely handled under BSL2(+) and whole blood specimens that carry a routine risk for bloodborne pathogens. They are evaluating and optimizing existing Luminex xMAP open-

architecture technology to determine antibodies to these pathogens. The requested changes include personnel changes, addition of hantavirus Andes and Sin Nombre strains, a description that sample processing will be carried out in a biosafety cabinet in ESH 7022, and decontamination process for equipment, changes to description of storage of agents, and additional safety practices for handling specimens that may contain risk group 3 pathogens.

Committee Recommendation: Complete a laboratory inspection by the end of the year.

Training: All training is complete and up to date.

Motion: Approved

Vote Counts: 12-0-0

8) **IBC#:** 20-05-029-ABL2

PI: Byrareddy, Siddappa

Title: Molecular, Immunological and Pathophysiology of emerging coronaviruses research including co-morbid conditions

Biohazardous Agents: Coronavirus SARS-CoV-2 (inactivated), Human cell line/cells/tissues, Human immunodeficiency virus types 1 and 2 (highly concentrated), Human immunodeficiency virus types 1 and 2 (not concentrated), Primary Human Cell Line, SARS-CoV-2 spike protein, SARS-CoV-2, Vero cells (African Green Monkey kidney), Lentiviral Vector, Plasmid, rRNA recombinant RNA

Applicable NIH Guidelines: III-D-1-a, III-D-3-a, III-D-4-a

Summary: This research aims to better understand SARS-CoV-2 disease mechanisms and identify potential therapeutic and diagnostic approaches. They culture and analyze viral strains in cell and primary-cell models, study immune and antibody responses, screen for antiviral compounds, and evaluate therapies in golden Syrian hamsters.

Committee Recommendation: Complete a laboratory inspection by the end of the year.

Training: All training is complete and up to date.

Motion: Approved

Vote Counts: 12-0-0

9) **IBC#:** 23-10-027-ABL2

PI: Al-Sadi, Rana

Title: Modulation of Intestinal Tight junction Barrier

Biohazardous Agents: *Bifidobacterium bifidum*, Human cell line/cells/tissues, *Lactobacillus acidophilus*, *Lactobacillus plantarum*, *Pactobacillus rhamnosus* GG, CRISPR-Cas9, miRNA micro, siRNA

Applicable NIH Guidelines: III-D-1-a, III-D-4-a

Summary: This protocol proposes to study intestinal epithelial tight junctions in health and disease states. The studies will use Caco-2 cells as an invitro model for the intestinal epithelium. Genes of interest in regulating the integrity of the tight junctions will be modulated by siRNA, miRNA and CRISPR-Cas9 techniques. Pro-biotic bacteria will be used to assess the integrity of the tight junctions in the Caco-2 cells and in a mouse model.

Committee Recommendation: None

Training: One individual needs to complete training.

Motion: Approved

Vote Counts: 12-0-0

10) **IBC#:** 23-07-021-BL2

PI: Cross, Shaun

Title: Evaluation of sequencing methods for swine-infecting viruses

Biohazardous Agents: Porcine Body Fluids

Applicable NIH Guidelines: Exempt

Summary: This research will employ a qPCR panel to identify four prevalent swine viruses present in porcine bodily fluids. Additionally, an advanced next-generation sequencing approach will be utilized to analyze the genetic diversity within these viral strains. The collection of porcine bodily fluids will be performed through a collaboration at UNL, while the viral genome isolation and sequencing procedures will take place at UNMC. All outlined procedures will be executed within a Class II Biological Safety Cabinet (BSC). Furthermore, stringent measures are proposed to ensure the inactivation of samples, effectively mitigating any concerns related to human infections.

Committee Recommendation: To streamline communication of the IBC review, they were advised to contact the Biosafety Team to set up a time to work through IBC comments and questions.

Training: All training is complete and up to date.

Motion: Conditionally Approved

Vote Counts: 12-0-0

11) **IBC#:** 24-08-025-BL2

PI: Krishnan, Mridula

Title: A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA

Biohazardous Agents: Human cell line/cells/tissues, mRNA

Applicable NIH Guidelines: III-C-1

Summary: This protocol describes a Phase II study to assess the safety and efficacy of the autogene mRNA vaccine cevumeran for treatment of PDAC (pancreatic ductal adenocarcinoma) in combination with atezolizumab and mFOLFIRINOX.

Committee Recommendation: Section II.1, rectify the repetitive primary and secondary objectives. Section II.3.A, correct the typo in "all items will be dispose of trace hazardous waste..."

Training: All training is complete and up to date.

Motion: Conditionally Approved

Vote Counts: 12-0-0

12) **IBC#:** 23-08-023-BL2

PI: Lunning, Matthew

Title: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel

Biohazardous Agents: Human cell line/cells/tissues, Retroviral vector

Applicable NIH Guidelines: III-C-1

Summary: Axicabtagene ciloleucel is an autologous treatment in which the patient's T cells are genetically engineered ex vivo, by retroviral transduction of a construct encoding an anti-CD19 chimeric antigen receptor (CAR), to target CD19 expression on B-cell malignancies.

Committee Recommendation: Update IRB numbers, as needed. Add location information to address where the thawing of product and apheresis are performed. Add information about the retroviral vector and particles. Indicate what disinfectant will be used on surfaces. Select RG2/BSL2 safety practices. Add a statement indicating that shipping procedures will be performed by trained personnel.

Training: Training is complete and up to date.

Motion: Conditionally Approved

Vote Counts: 12-0-0

13) **IBC#:** 04-01-003-BL2

PI: Johnson, Keith

Title: Cell adhesion related proteins in carcinomas

Biohazardous Agents: Human cell line/cells/tissues, Lentiviral Vector, Plasmid, Retroviral vector

Applicable NIH Guidelines: III-D-1-a, III-D-3-a

Summary: This study investigates how altering gene expression in cultured cells affects cellular function and behavior. Researchers will use plasmid, retroviral, and lentiviral vectors, including lentiviral CRISPR/Cas9 guide RNA systems to either express genes or reduce the expression of selected targets. The modified cells will then be evaluated through biochemical studies, immunofluorescence, and assays measuring changes in cell growth, migration, and invasion.

Committee Recommendation: Schedule a laboratory inspection.

Training: All training is complete and up to date.

Motion: Approved

Vote Counts: 12-0-0

14) **IBC#:** 23-07-022-ABL2

PI: Chand, Subhash

Title: Impact of cannabidiol on HIV infection and methamphetamine abuse associated neuroinflammation

Biohazardous Agents: Human cell line/cells/tissues, Human immunodeficiency virus types 1 and 2 (not concentrated)

Applicable NIH Guidelines: Exempt

Summary: This study examines how cannabidiol (CBD) affects neuroinflammation associated with HIV infection and methamphetamine exposure. Researchers will analyze cell cultures and humanized mice to assess changes in inflammatory pathways and extracellular vesicle contents.

Committee Recommendation: None

Training: All training is complete and up to date.

Motion: Approved

Vote Counts: 12-0-0

15) **IBC#:** 23-07-018-ABL2

PI: Holstein, Sarah

Title: Evaluation of novel agents in mouse models of multiple myeloma

Biohazardous Agents: Human cell line/cells/tissues, Lentiviral Vector

Applicable NIH Guidelines: III-D-1-a, III-D-3-a, III-D-4-a

Summary: This protocol uses human cancer cell lines obtained from commercial sources and lentiviral transduction to label the cells. These cells will then be injected into mice to develop cancers that can be imaged.

Committee Recommendation: Update IACUC to be consistent with Section XII (site of study). If no animal transport is occurring, remove the information.

Training: All training is complete and up to date.

Motion: Conditionally Approved

Vote Counts: 12-0-0

16) **IBC#:** 23-07-016-BL2

PI: Broadhurst, Jana

Title: Schistosoma testing

Biohazardous Agents: Human cell line/cells/tissues, *Schistosoma* spp

Applicable NIH Guidelines: Exempt

Summary: This protocol aims to develop diagnostic and testing methods for *Schistosoma haematobium* using LAMP and PCR. The samples to be tested are human urine samples collected in Ethiopia.

Committee Recommendation: Schedule a laboratory inspection. Provide information on decontamination practices for receiving urine samples. Inform personnel on possible hazards that may be present.

Training: All training is complete and up to date.

Motion: Conditionally Approved

Vote Counts: 12-0-0

17) **IBC#:** 20-08-040-BL2

PI: Lunning, Matthew

Title: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

Biohazardous Agents: Human cell line/cells/tissues, Lentiviral Vector

Applicable NIH Guidelines: III-C-1

Summary: This protocol describes the use of CAR T-cell therapy that does not meet commercial release standards but is otherwise considered safe for use on compassionate grounds at the treating physician's discretion.

Committee Recommendation: None


Training: All training is complete and up to date.

Motion: Approved

Vote Counts: 12-0-0

There being no further business, Dr. McMillan adjourned the meeting at 3:35pm

Respectfully Submitted,



JoEllyn McMillan, PhD

Chair, IBC

JM

ADDENDUM
July 9, 2026
IBC REVIEW LETTER/EMAIL TO INVESTIGATORS

<u>IBC #</u>	<u>Date of Letter/Email</u>
26-06-014-Pending	7/10/2026
26-06-015-Pending	7/09/2026
26-06-016-Pending	7/09/2026
23-11-031-BL2	7/09/2026
25-02-009-ABL2	7/10/2026
26-01-001-BL3	7/09/2026
20-03-022-BL2	7/09/2026
20-05-029-ABL2	7/09/2026
23-10-027-ABL2	7/09/2026
23-07-021-BL2	7/10/2026
24-08-025-BL2	7/10/2026
23-08-023-BL2	7/10/2026
04-01-003-BL2	7/10/2026
23-07-022-ABL2	7/10/2026
23-07-018-ABL2	7/10/2026
23-07-016-BL2	7/10/2026
20-08-040-BL2	7/10/2026